



ASH2022 abstracts: What's hot in multiple myeloma?

To help navigate the exciting content being presented at the 64th ASH Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.



Click
the abstracts
to view



Scientific Education Support

Newly diagnosed multiple myeloma

- | | | |
|-----|--|---------------------|
| 569 | <u>A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial</u> | Salomon Manier |
| 570 | <u>Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant – Data from the Myeloma XI Trial</u> | Charlotte Pawlyn |
| 643 | <u>Tracking the Earliest Genomic Events in Multiple Myeloma Life-History</u> | Anthony Cirrincione |
| 644 | <u>Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients – Meta-Analysis of 5,808 Trial Patients</u> | Martin F Kaiser |
| 754 | <u>Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial</u> | John R Jones |
| 762 | <u>Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) – Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation</u> | Kwee Yong |
| 865 | <u>Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow</u> | Laura Notarfranchi |
| 870 | <u>Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)</u> | Ben A Derman |
| 969 | <u>Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease</u> | Sunil Lakhwani |

Relapsed/refractory multiple myeloma

- | | | |
|-----|---|----------------------|
| 159 | <u>Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the MagnetisMM-3 Study</u> | Nizar Jacques Bahlis |
| 160 | <u>Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study</u> | Emma Searle |
| 171 | <u>Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study</u> | Hira S Mian |
| 249 | <u>Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy</u> | Santiago Thibaud |
| 361 | <u>KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation</u> | Saad Usmani |

Other plasma cell dyscrasias

- | | | |
|-----|---|--------------------------------|
| 107 | <u>Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istoppmm Cohort</u> | Elias Eythorsson |
| 108 | <u>Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy</u> | Romanos Sklavenitis-Pistofidis |
| 118 | <u>Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)</u> | Maria-Victoria Mateos |
| 757 | <u>Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma- Results of the Ascent Trial</u> | Shaji K Kumar |
| 760 | <u>Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis in the Phase 3 VITAL Study Consistent after Adjustment for Key Baseline Variables</u> | Morie A Gertz |
| 761 | <u>Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network</u> | Efstathios Kastritis |
| 967 | <u>Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istoppmm Study</u> | Robert Palmason |



Follow us on Twitter to keep up to date
with the latest from the 64th ASH Annual
Meeting and Exposition!

@MM_Hub

#ASH22

multiplemyelomahub.com